

Appendix 4D

Financial statements for the half-year ended 31 December 2024

as required by ASX listing rule 4.2A

1. Company details

Name of entity:	Clarity Pharmaceuticals Ltd
ABN:	36 143 005 341
Reporting period:	Half Year ended 31 December 2024
Previous period:	Half Year ended 31 December 2023

2. Results for announcement to the market

				\$'000
Revenue from ordinary activities	up	0%	to	0
Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd	up	37%	to	(23,582)
Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd	up	37%	to	(23,582)

Dividends

There were no dividends paid, recommended, or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$23,581,592.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2024.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	39.7	20.2

4. Control gained over entities

Not applicable

Appendix 4D

Financial statements for the half-year ended 31 December 2024

as required by ASX listing rule 4.2A

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

This report is based on the consolidated financial statements for the half-year ended 31 December 2024 which have been reviewed by Grant Thornton who have issued an unmodified opinion.

8. Attachments

Details of attachments (if any):

The Half Year Financial Statements of Clarity Pharmaceuticals Ltd for the period ended 31 December 2024 are attached.

9. Signed

As authorised by the Board of Directors



Robert Vickery
Company Secretary
28 February 2025

For personal use only